IP Library Granted Patent US 8,044,099
Granted Patent B2
US 8,044,099 · App. 11/011,776 · Granted Oct 25, 2011

Synthetic bifunctional molecules containing drug moiety and pharmacokinetic modulating moiety

Assignee: The Board of Trustees of the Leland Stanford Junior University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,044,099
App. No.
11/011,776
Granted
Oct 25, 2011
Kind
B2
Abstract

Bifunctional molecules and methods for their use are provided. The subject bifunctional molecules are conjugates of a drug moiety and a pharmacokinetic modulating moiety, where these two moieties are optionally joined by a linking group. The bifunctional molecules are further characterized in that they exhibit at least one modulated pharmacokinetic property upon administration to a host as compared to a free drug control. The subject bifunctional molecules find use in a variety of therapeutic applications.

Claims (6)

1. A synthetic bifunctional molecule of less than about 5000 daltons consisting of a drug moiety and a pharmacokinetic modulating moiety, wherein said drug moiety and said pharmacokinetic modulating moiety are different and have been chosen so that said pharmacokinetic modulating moiety modulates at least one pharmacokinetic property of said drug moiety upon administration of said synthetic bifunctional molecule to a host as compared to a free drug control comprising said drug moiety, wherein said pharmacokinetic property is selected from the group consisting of half-life, hepatic first-pass metabolism, volume of distribution and degree of blood protein binding, and wherein the pharmacokinetic modulating moiety is selected from the group consisting of a ligand for α-1 acid glycoprotein, sulfisoxazole and naproxen.

2. The bifunctional molecule according to claim 1 , wherein said pharmacokinetic modulating moiety is a ligand for α-1 acid glycoprotein.

3. The bifunctional molecule according to claim 2 , wherein said pharmacokinetic modulating moiety is a small neutral or basic molecule.

4. The bifunctional molecule according to claim 3 , wherein said pharmacokinetic modulating moiety selected from the group consisting of: propanolol, chlorpromazine, dipyrimadole, metoclopromide, aprindine and verapamil.

5. The bifunctional molecule according to claim 1 , wherein said pharmacokinetic modulating moiety is sulfisoxazole.

6. The bifunctional molecule according to claim 1 , wherein said pharmacokinetic modulating moiety is naproxen.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2005
From: BRIESEWITZ, ROGER; WANDLESS, THOMAS J.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 016162/0266 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2005
From: HOWARD HUGHES MEDICAL INSTITUTE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 016162/0288 →
Continuity (3)
Continuation 09716841 · Nov 17, 2000
Provisional Application 60166633 · Nov 19, 1999
Related Publication 20050209265A1 · Sep 22, 2005